Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Down 25.9% in December

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the recipient of a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 26,900 shares, a decline of 25.9% from the November 30th total of 36,300 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average trading volume of 119,300 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Ratings Changes

Separately, Craig Hallum set a $1.50 price objective on shares of Xtant Medical and gave the stock a “buy” rating in a report on Friday, October 18th.

Xtant Medical Price Performance

NYSEAMERICAN XTNT traded up $0.03 on Friday, reaching $0.46. 75,904 shares of the stock were exchanged, compared to its average volume of 113,672. The stock has a market cap of $64.51 million, a price-to-earnings ratio of -3.57 and a beta of 0.34. Xtant Medical has a one year low of $0.33 and a one year high of $1.31. The company has a current ratio of 2.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.42.

Xtant Medical (NYSEAMERICAN:XTNT) last released its earnings results on Tuesday, November 12th. The medical device company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The company had revenue of $27.94 million during the quarter. Xtant Medical had a negative return on equity of 37.07% and a negative net margin of 15.45%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Xtant Medical stock. Evernest Financial Advisors LLC bought a new stake in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 40,000 shares of the medical device company’s stock, valued at approximately $27,000. 69.33% of the stock is owned by institutional investors.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.